English  |  正體中文  |  简体中文  |  2850591  
???header.visitor??? :  44694494    ???header.onlineuser??? :  1194
???header.sponsordeclaration???
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
???ui.leftmenu.abouttair???

???ui.leftmenu.bartitle???

???index.news???

???ui.leftmenu.copyrighttitle???

???ui.leftmenu.link???

"fukuoka m"???jsp.browse.items-by-author.description???

???jsp.browse.items-by-author.back???
???jsp.browse.items-by-author.order1??? ???jsp.browse.items-by-author.order2???

Showing items 1-10 of 13  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page

Institution Date Title Author
臺大學術典藏 2022-05-10T08:10:07Z Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival Lee C.K.; Davies L.; Wu Y.-L.; Mitsudomi T.; Inoue A.; Rosell R.; Zhou C.; Nakagawa K.; Thongprasert S.; Fukuoka M.; Lord S.; Marschner I.; YU-KANG TU; Gralla R.J.; Gebski V.; Mok T.; Yang J.C.-H.
臺大學術典藏 2020-05-26T09:27:19Z Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma Mok T.S; Wu Y.-L; Thongprasert S; Yang C.-H; Chu D.-T; Saijo N; Sunpaweravong P; Han B; Margono B; Ichinose Y; Nishiwaki Y; Ohe Y; CHIH-HSIN YANG; Chewaskulyong B; Jiang H; Duffield E.L; Watkins C.L; Armour A.A; Fukuoka M.
臺大學術典藏 2020-05-26T09:27:15Z Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS) Thongprasert S;Duffield E;Saijo N;Wu Y.-L;Chih-Hsin Yang;Chu D.-T;Liao M;Chen Y.-M;Kuo H.-P;Negoro S;Lam K.C;Armour A;Magill P;Fukuoka M.; Thongprasert S; Duffield E; Saijo N; Wu Y.-L; CHIH-HSIN YANG; Chu D.-T; Liao M; Chen Y.-M; Kuo H.-P; Negoro S; Lam K.C; Armour A; Magill P; Fukuoka M.
臺大學術典藏 2020-05-26T09:27:11Z Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non - small-cell lung cancer in Asia (IPASS) Fukuoka M;Wu Y.-L;Thongprasert S;Sunpaweravong P;Leong S.-S;Sriuranpong V;Chao T.-Y;Nakagawa K;Chu D.-T;Saijo N;Duffield E.L;Rukazenkov Y;Speake G;Jiang H;Armour A.A;To K.-F;Chih-Hsin Yang;Mok T.S.K.; Fukuoka M; Wu Y.-L; Thongprasert S; Sunpaweravong P; Leong S.-S; Sriuranpong V; Chao T.-Y; Nakagawa K; Chu D.-T; Saijo N; Duffield E.L; Rukazenkov Y; Speake G; Jiang H; Armour A.A; To K.-F; CHIH-HSIN YANG; Mok T.S.K.
臺大學術典藏 2020-05-26T09:27:01Z Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: Post hoc analyses from the IPASS study Wu Y.-L;Fukuoka M;Mok T.S.K;Saijo N;Thongprasert S;Chih-Hsin Yang;Chu D.-T;Chih-Hsin Yang;Rukazenkov Y.; Wu Y.-L; Fukuoka M; Mok T.S.K; Saijo N; Thongprasert S; CHIH-HSIN YANG; Chu D.-T; CHIH-HSIN YANG; Rukazenkov Y.
臺大學術典藏 2020-05-26T09:26:58Z Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III iressa pan-ASia study (IPASS) Chih-Hsin Yang;Wu Y.-L;Chan V;Kurnianda J;Nakagawa K;Saijo N;Fukuoka M;Mcwalter G;Mccormack R;Mok T.S.K.; CHIH-HSIN YANG; Wu Y.-L; Chan V; Kurnianda J; Nakagawa K; Saijo N; Fukuoka M; McWalter G; McCormack R; Mok T.S.K.
臺大學術典藏 2020-05-26T09:26:41Z Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival Chih-Hsin Yang;Mok T;Gebski V;Gralla R.J;Tu Y.-K;Marschner I;Lord S;Fukuoka M;Thongprasert S;Nakagawa K;Zhou C;Rosell R;Inoue A;Mitsudomi T;Wu Y.-L;Davies L;Lee C.K; Lee C.K; Davies L; Wu Y.-L; Mitsudomi T; Inoue A; Rosell R; Zhou C; Nakagawa K; Thongprasert S; Fukuoka M; Lord S; Marschner I; Tu Y.-K; Gralla R.J; Gebski V; Mok T; CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:40Z Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC Fukuoka M.;Rukazenkov Y;Haddad V;Young H;Mok T.S.K;Yang J.-J;Ichinose Y;Ohe Y;Sunpaweravong P;Chewaskulyong B;Margono B;Han B;Chih-Hsin Yang;Thongprasert S;Saijo N;Wu Y.-L; Wu Y.-L; Saijo N; Thongprasert S; CHIH-HSIN YANG; Han B; Margono B; Chewaskulyong B; Sunpaweravong P; Ohe Y; Ichinose Y; Yang J.-J; Mok T.S.K; Young H; Haddad V; Rukazenkov Y; Fukuoka M.
臺大學術典藏 2020-05-26T09:26:28Z The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer Chih-Hsin Chih-Hsin Yang;Mok T;Gralla R;Gebski V;Davies L;Asher R;Mitsudomi T;Fukuoka M;Rosell R;Sequist L;Wu Y.L;Marschner I;Lord S;Lee C.K; Lee C.K; Lord S; Marschner I; Wu Y.L; Sequist L; Rosell R; Fukuoka M; Mitsudomi T; Asher R; Davies L; Gebski V; Gralla R; Mok T; Chih-Hsin CHIH-HSIN YANG
臺大學術典藏 2020-05-26T09:26:26Z Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations Nakagawa K.;Fukuoka M;Morita S;Shimazaki M;Kaneko Y;Akazawa R;Takeda K;Nakagawa T;Kang J.-H;Takeda K;Inoue A;Kiura K;Kim S.-W;Nishio M;Chih-Hsin Yang;Tsai C.-M;Azuma K;Park K;Seto T;Hayashi H;Nokihara H;Murakami H; Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K.

Showing items 1-10 of 13  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page